A Sub-Leakage pW-Power Hz-Range Relaxation Oscillator Operating with 0.3V-1.8V Unregulated Supply

A pW-power versatile relaxation oscillator operating from sub-threshold (0.3V) to nominal voltage (1.8V) is presented, having Hz-range frequency under sub-pF capacitor. The wide voltage and low sensitivity of frequency/absorbed current to the supply allow the suppression of the voltage regulator, and direct powering from harvesters (e.g., solar cell, thermal from machines) or 1.2-1.5V batteries. A 180nm testchip exhibits a frequency of 4 Hz , 10%/V supply sensitivity at 0.3-1.8V, 8-18pA current, 4%/°C thermal drift from -20°C to 40°C

Fully Synthesizable, Rail-to-Rail Dynamic Voltage Comparator for Operation down to 0.3V

A novel rail-to-rail dynamic voltage comparator is presented in this paper. The proposed circuit is fully synthesizable, as it can be designed with automated digital design flows and standard cells, and can operate at very low voltages down to deep sub-threshold. Post-layout simulations show correct operation for rail-to-rail common-mode inputs at a supply voltage VDD down to 0.3 V. At such voltage, the input offset voltage standard deviation is less than 28 mV (8 mV) over the rail-to-rail common-mode input range (around VDD/2). The digital nature of the comparator and its ability to operate down to deep sub-threshold voltages allow its full integration with standard-cell digital circuits in terms of both design and voltage domain. The ease of design, the low area and the voltage scalability make the proposed comparator very well suited for sensor nodes, integrated circuits for the Internet of Things and related applications

Design of Relaxation Digital-to-Analog Converters for Internet of Things Applications in 40nm CMOS

A 10-bit-400kS/s and a 10-bit-2MS/s Relaxation Digital to Analog Converters (ReDAC) in 40nm are presented in this paper. The two ReDACs operate from a 600mV power supply, occupy a silicon area of less than 1,000um^2. The first/second DAC achieve a maximum INL of 0.33/0.72 LSB and a maximum DNL of 0.2/1.27 LSB and 9.9/9.4 ENOB based on post-layout simulations. The average energy per conversion is less than 1.1/0.73pJ, corresponding to a FOM of 1.1/1.08 fJ/(conv. step), which make them well suited to Internet of Things (IoT) applications. (PDF) Design of Relaxation Digital-to-Analog Converters for Internet of Things Applications in 40nm CMOS. Available from: https://www.researchgate.net/publication/336552301_Design_of_Relaxation_Digital-to-Analog_Converters_for_Internet_of_Things_Applications_in_40nm_CMOS [accessed Nov 16 2019]

Passenger car equivalent for heavy vehicles crossing turbo-roundabouts

Turbo-roundabouts represent an innovative scheme of modern roundabouts which provides a spiraling traffic flow and requires drivers to choose their direction before entering the intersection, since raised lane separators mark the lanes on the ring. The configuration of the turbo-roundabout makes that patterns of conflict at entries with one and two conflicting traffic streams can coexist. This paper presents research efforts aimed at measuring quantitatively the effect of heavy vehicles on operational conditions of a turbo-roundabout. The study starts from the initial belief that the greatest constraints to the vehicular trajectories imposed by the turbo-roundabout necessarily imply that the impact of heavy vehicles on the quality of traffic flow is more unfavorable than on other modern roundabouts. Microsimulation revealed as a useful tool when the variation of the traffic quality in turbo-roundabouts should be evaluated in presence of mixed fleets, each having different percentages of heavy vehicles; indeed, it allowed to isolate traffic conditions difficult to observe on field and replicate them to have a number of data as much as possible numerous. Entry capacity values for each entry lane of the turbo-roundabout were obtained by microsimulation, varying the percentage of heavy vehicles for entering flows. Nonlinear regression analysis of simulation data allowed to derive the behavioral parameters for heterogeneous populations of users and, ultimately, composed exclusively of heavy vehicles. The capacity functions thus obtained allowed us to determine how the passenger car equivalent (PCE) varies with the percentage of heavy vehicles and circulating flows for each entry lane of the turbo-roundabout. The results of this study indicate that there is a need to distinguish the impact of heavy vehicles when analyzing the capacity of a turbo-roundabout. When the traffic stream contains a significant number of heavy vehicles, a larger PCE effect would be expected. This effect should be accounted for in the estimation of the turbo-roundabout capacity. Lastly it should be emphasized that an important aspect of the research consists in having identified a methodology for assessing the impact of heavy vehicles on the quality of traffic flow, that can be applied to different patterns of intersection

Marine pharmacology in 2009-2011: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action.

The peer-reviewed marine pharmacology literature from 2009 to 2011 is presented in this review, following the format used in the 1998–2008 reviews of this series. The pharmacology of structurally-characterized compounds isolated from marine animals, algae, fungi and bacteria is discussed in a comprehensive manner. Antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral pharmacological activities were reported for 102 marine natural products. Additionally, 60 marine compounds were observed to affect the immune and nervous system as well as possess antidiabetic and anti-inflammatory effects. Finally, 68 marine metabolites were shown to interact with a variety of receptors and molecular targets, and thus will probably contribute to multiple pharmacological classes upon further mechanism of action studies. Marine pharmacology during 2009–2011 remained a global enterprise, with researchers from 35 countries, and the United States, contributing to the preclinical pharmacology of 262 marine compounds which are part of the preclinical pharmaceutical pipeline. Continued pharmacological research with marine natural products will contribute to enhance the marine pharmaceutical clinical pipeline, which in 2013 consisted of 17 marine natural products, analogs or derivatives targeting a limited number of disease categories

L’emorroidectomia secondo Milligan-Morgan e la mucoprolassectomia con stapler. Valutazione clinica comparativa dei risultati

The aim of this retrospective study was to assess the results of treatment for hemorrhoids by Milligan-Morgan hemorrhoidectomy and by stapled mucoprolapsectomy in terms of operative time, postoperative pain, lenght of hospital stay, incidence of early and late complications, time to return to work and to normal social activities and patient satisfaction. Between January 2002 and December 2003, a total of 65 patients with hemorrhoids (35 men and 30 women with a mean age of 46.9 years) underwent surgical treatment: 41 patients underwent conventional hemorrhoidectomy and 24 patients stapled mucoprolapsectomy. All patients were contacted by phone or were reviewed in the outpatient clinic with a mean follow-up of 2 months (range 8-31). The Authors emphasize that it is difficult to make an objective comparison between hemorrhoidectomy and stapled mucoprolapsectomy because the two procedures are completely different in terms of rationale and technique; however, stapled circumferential mucosectomy in their experience causes less postoperative pain and bleeding and can be considered a valid therapeutic option for third- and fourth-degree disease

Ptaquiloside, the major carcinogen of bracken fern, in the pooled raw milk of healthy sheep and goats: an underestimated, global concern of food safety

Bracken fern (Pteridium aquilinum) is a worldwide plant containing toxic substances, which represent an important chemical hazard for animals, including humans. Ptaquiloside, 1, a norsesquiterpenoid glucoside, is the major carcinogen of bracken detected in the food chain, particularly in the milk from farm animals. To date, ptaquiloside has been shown in the milk of cows feeding on a diet containing bracken fern. This is the first study that shows the systematic detection of ptaquiloside, 1, and reports its direct quantitation in pooled raw milk of healthy sheep and goats grazing on bracken. Ptaquiloside, 1, was detected by a sensitive method based on the chemical conversion of ptaquiloside, 1, into bromopterosine, 4, following gas chromatography–mass spectrometry (GC–MS) analysis. The presence of ptaquiloside, 1, possibly carcinogenic to humans, in the milk of healthy animals is an unknown potential health risk, thus representing a harmful and potential global concern of food safety

Bisphenol A Is Released from Used Polycarbonate Animal Cages into Water at Room Temperature

doi:10.1289/ehp.5993Bisphenol A (BPA) is a monomer with estrogenic activity that is used in the production of food packaging, dental sealants, polycarbonate plastic, and many other products. The monomer has previously been reported to hydrolyze and leach from these products under high heat and alkaline conditions, and the amount of leaching increases as a function of use. We examined whether new and used polycarbonate animal cages passively release bioactive levels of BPA into water at room temperature and neutral pH. Purified water was incubated at room temperature in new polycarbonate and polysulfone cages and used (discolored) polycarbonate cages, as well as control (glass and used polypropylene) containers. The resulting water samples were characterized with gas chromatography/mass spectrometry (GC/MS) and tested for estrogenic activity using an MCF-7 human breast cancer cell proliferation assay. Significant estrogenic activity, identifiable as BPA by GC/MS (up to 310 µg/L), was released from used polycarbonate animal cages. Detectable levels of BPA were released from new polycarbonate cages (up to 0.3 µg/L) as well as new polysulfone cages (1.5 µg/L), whereas no BPA was detected in water incubated in glass and used polypropylene cages. Finally, BPA exposure as a result of being housed in used polycarbonate cages produced a 16% increase in uterine weight in prepubertal female mice relative to females housed in used polypropylene cages, although the difference was not statistically significant. Our findings suggest that laboratory animals maintained in polycarbonate and polysulfone cages are exposed to BPA via leaching, with exposure reaching the highest levels in old cages.Support during the preparation of this manuscript was provided by grants from the National Institutes of Health (CA50354) and the University of Missouri (VMFC0018) to W.V.W., NIH (ES08293 and ES11283) to F.v.S., and the U.S.G.S

International Guillain-Barré Syndrome Outcome Study (IGOS): protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multi-centre cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within two weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1000 patients with a follow-up of 1-3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1400 participants from 143 active centres in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modelling, treatment effects and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS. ClinicalTrials.gov Identifier: NCT01582763